Details:
Under the terms of the agreement, Searchlight will have sales and marketing rights for DONESTA® in Canada. DONESTA (estetrol) phase 3 clinical program, which demonstrated a meaningful reduction in the frequency and severity of vasomotor symptoms compared to placebo.
Lead Product(s): Estetrol
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Donesta
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: SEARCHLIGHT PHARMA INC
Deal Size: $17.9 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 26, 2023
Details:
Under the agreement, Searchlight will have the Canadian rights to Donesta, a next generation orally administered Estetrol (E4)-based hormone therapy product, for the treatment of the symptoms of menopause.
Lead Product(s): Estetrol
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Donesta
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: SEARCHLIGHT PHARMA INC
Deal Size: $18.7 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 31, 2023
Details:
Estelle® is a novel patent protected combined oral contraceptive pill containing 3 mg drospirenone (DRSP) and 15 mg estetrol (E4). E4 is a naturally produced estrogen during pregnancy, which can now be made from a plant source.
Lead Product(s): Estetrol,Drospirenone
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Estelle
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 10, 2023
Details:
Health Canada has accepted Searchlight Pharma's New Drug Submission for a novel combined oral contraceptive (COC) product. Innovative product candidate developed by Mithra containing the unique native estrogen Estetrol (E4) and drospirenone (DRSP).
Lead Product(s): Estetrol,Drospirenone
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 20, 2020
Details:
In light of covid-19 crisis, Mithra confirms that E4 Comfort studies are still ongoing at this time, but that current patient recruitment has been delayed or put on hold in some countries.
Lead Product(s): Estetrol
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 01, 2020